Genesis Genomics Inc. (Genesis Genomics) has received $1.9 million contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). The funding supports an innovative research and development project that will assist Genesis Genomics in early cancer detection. This will support the company in a two-year project to identify diagnostic genetic cancer markers using mitochondrial DNA-based biomarkers.
Our government is committed to building a competitive advantage for the Canadian private sector and supports these leading-edge technology solutions, said Greg Rickford, Member of Parliament for Kenora. The Government of Canada is investing in science and technology to create jobs, strengthen the economy and improve Canadians’ quality of life.
Genesis Genomics is launching a new project for Accelerated mtDNA Genome Biomarker Discovery. This project, based on a new, novel class of mtDNA molecules, will develop screening tests for early detection of cancer which can lead to effective early treatment. The mitochondrion is responsible for many of the cellular processes associated with the growth of cancerous tumours; such early detection of cancerous tumours would greatly increase the opportunity for successful treatment and have a significant impact in improving the quality of life of Canadians.
Genesis Genomics is a biotechnology company engaged in the discovery, development and commercial application of mitochondrial DNA (mtDNA) based biomarkers for a wide spectrum of human diseases.
The NRC Industrial Research Assistance Program (NRC-IRAP) provides a range of both technical and business-oriented advisory services along with necessary financial support to qualified innovative Canadian small- and medium-sized enterprises.